Key Highlights

  • Shuttle Pharmaceuticals (NASDAQ:SHPH) was down 12.43% at USD 4.51; 1-for-10 reverse split on June 11, 2026.
  • InMed Pharmaceuticals (NASDAQ:INM) was down 9.52% at USD 1.52; cash runway only into mid-November 2026.
  • Entera Bio (NASDAQ:ENTX) was down 7.87% at USD 2.81; USD 275.0 million July 2026 placement.
  • BridgeBio Oncology Therapeutics (NASDAQ:BBOT) was down 7.76% at USD 2.14; cash funds operations into 2028.
  • Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) was down 7.69% at USD 0.18; Nu-3 data guided for the first quarter of 2027.

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) (down USD 0.6402, 12.43%): Giving Back Ground After a Reverse Split

Shuttle Pharmaceuticals (NASDAQ:SHPH) was down 12.43%, or USD 0.6402, at USD 4.51 in pre-market trading on November 4, 2026, implying a Tuesday close of about USD 5.15 (calculated). No company press release or regulatory filing dated November 2 to November 4, 2026 was identified, so no catalyst was found; the move looks like trading on a small share base, which is an inference.

A March 6, 2026 release described a public offering of about USD 3.5 million gross, roughly USD 0.50 per share before the 1-for-10 reverse split (calculated). Detailed recent cash figures were not confirmed, and repeated small raises point to dilution risk.

InMed Pharmaceuticals Inc. (NASDAQ:INM) (down USD 0.1599, 9.52%): Weak Cash Meets a Merger Vote

InMed Pharmaceuticals (NASDAQ:INM) was down 9.52%, or USD 0.1599, at USD 1.52 in pre-market trading on November 4, 2026. The decline follows first quarter fiscal 2027 results published on November 3, 2026, which showed a net loss of USD 2,330,778 against USD 1,726,899 a year earlier.

Cash fell to USD 1,094,488 from USD 2,194,413 at June 30, 2026, and Equity was a Deficit of USD 1,199,396. The company expects cash to last only into mid-November 2026. A Shareholder meeting on the proposed Mentari Therapeutics merger is set for November 4, 2026, and Mentari has announced private placements of about USD 490 million. Risks include a failed vote, dilution and the March 15, 2027 Nasdaq equity deadline.

Entera Bio Ltd. (NASDAQ:ENTX) (down USD 0.2400, 7.87%): Well Funded but Still Slipping

Entera Bio (NASDAQ:ENTX) was down 7.87% at USD 2.81 in pre-market trading on November 4, 2026, against a November 3 close of about USD 3.05. No announcement dated November 2 to November 4, 2026 was identified.

An August 7, 2026 release said the FDA accepted a single placebo controlled Phase 3 design for EB613, an oral PTH(1-34) tablet for osteoporosis, in about 750 women, with topline data in the second half of 2028. The July 2026 private Placement raised about USD 275.0 million gross and, the company said, extends its runway into 2030. Risks include Warrant dilution and a long wait for results.

BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT) (down USD 0.1800, 7.76%): Continued Weakness Despite Strong Data

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) was down 7.76%, or USD 0.1800, at USD 2.14 in pre-market trading on November 4, 2026. No company announcement dated November 2 to November 4, 2026 was identified as a catalyst. The level sits about 35% below the USD 3.31 inducement option price of October 12, 2026 (calculated).

On September 8, 2026 the company reported Phase 1 data for BBO-8520, a KRAS G12C inhibitor, with a 63% objective response rate (26 of 41 patients) as monotherapy, yet shares fell 23.76% that day. Cash and investments were USD 344.1 million at June 30, 2026, which the company said funds operations into 2028. Risks include disappointing trials and future equity raises.

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) (down USD 0.0150, 7.69%): Dilution Worries Weigh on a Sub-USD 1 Stock

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) was down 7.69%, or USD 0.0150, at USD 0.18 in pre-market trading on November 4, 2026. No company announcement dated November 2 to November 4, 2026 was identified. The stock fell 19.31% on October 21, 2026, the day it presented laboratory data on Nu-3 at IDWeek 2026, and is about 85% below its May 18, 2026 level of USD 1.20 (calculated).

The first Phase 2a patient was dosed on September 24, 2026, with topline data guided for the first quarter of 2027. The company completed a USD 7.5 million Series C convertible preferred placement, which could convert into up to 4,512,400 common shares. Shareholders were asked to approve a reverse split of up to 1 for 20; the vote outcome and current cash balance were not identified. Dilution and Liquidity Risk apply.

Where Things Stand

All five stocks are clinical stage biotechs, and four of the five had no identified announcement for November 4, 2026. The exception is InMed (NASDAQ:INM), where weak results and a merger vote frame the move. Watch third quarter reports, financing and dilution updates, the Mentari vote outcome and trial milestones.